Viatris Greater China — Selling, general and administration decreased by 22.6% to $111.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.7%, from $110.00M to $111.90M. Over 3 years (FY 2022 to FY 2025), Greater China — Selling, general and administration shows relatively stable performance with a 1.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
High spending may signal investment in market expansion, while declining spending may indicate cost-cutting or operational efficiency efforts.
Operating expenses incurred to support the sales, marketing, and administrative functions of the Greater China business...
Standard SG&A reporting for business segments across the pharmaceutical sector.
vtrs_segment_greater_china_selling_general_and_administration| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $123.23M | $123.23M | $123.23M | $123.23M | $132.03M | $132.03M | $132.03M | $132.03M | $116.40M | $130.80M | $134.70M | $136.60M | $110.00M | $124.60M | $133.00M | $144.60M | $111.90M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +7.1% | +0.0% | +0.0% | +0.0% | -11.8% | +12.4% | +3.0% | +1.4% | -19.5% | +13.3% | +6.7% | +8.7% | -22.6% |
| YoY Change | — | — | — | — | +7.1% | +7.1% | +7.1% | +7.1% | -11.8% | -0.9% | +2.0% | +3.5% | -5.5% | -4.7% | -1.3% | +5.9% | +1.7% |